Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 23

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 23
---
                          
 business strategy and plans; |

| ● | the                                                                           
 potential market for our product candidate, if approved for sale in the U.S.; |

| ● | new                                                                                                
 regulatory pronouncements and changes in regulatory guidelines and timing of regulatory approvals; |

| ● | general                                    
 and industry-specific economic conditions; |

| ● | variations                                                                                                                   
 in our quarterly financial and operating results, including the rate at which we incur negative cash flow in future periods; |

| ● | additions                              
 to or departures of our key personnel; |

| ● | changes                                                                                           
 in market valuations of other companies that operate in our business segments or in our industry; |

| ● | lack                  
 of trading liquidity; |

| ● | if                                                                                                                            
 our product is approved and becomes available for us to sell in the U.S., whether we ultimately achieve profitability or not; |

| ● | changes                       
 in accounting principles; and |

| ● | general                                                 
 market conditions, economic and other external factors. |

The market prices of the securities of early-stage companies, particularly companies like ours that are seeking to obtain regulatory approval of their product candidate and do not yet generate operating revenue, have been highly volatile and are likely to remain highly volatile in the future. This volatility has often been unrelated to the operating performance of particular companies. In the past, companies that experience volatility in the market price of their securities have often faced securities class action litigation. Whether or not meritorious, litigation brought against us could result in substantial costs, divert our management’s attention and resources and harm our financial condition and results of operations.

| 13 |

Although we have no preferred stock outstanding as of the date hereof and we have currently no intention to issue any preferred stock, our common stockholders could be adversely affected by the issuance by us of preferred stock in the future, if any.

Our certificate of incorporation does not restrict our ability to offer one or more series of preferred stock, any or all of which could rank equally with or have preferences over our common stock as to dividend payments, voting rights, rights upon liquidation or other types of rights. Our board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences and the number of shares constituting any series or the designation of such series. In the case our board of directors decides to issue any preferred stock, we would have no obligation to consider the specific interests of the holders of common stock in creating any such series